Arcus Biosciences Q4 Earnings Call Highlights

2 hours ago 1

MarketBeat

Sat, February 28, 2026 astatine 4:05 PM CST 8 min read

Arcus Biosciences logo

Updated ARC-20 single-agent information amusement casdatifan (100 mg QD) with a confirmed ORR rising to 45% and median PFS of 15.1 months, which Arcus says compares favorably to belzutifan successful late-line ccRCC.
Phase III PEAK-1 is actively enrolling (casdatifan + cabozantinib vs cabozantinib alone) with a year-end enrollment extremity arsenic portion of a broader propulsion to physique a TKI‑sparing frontline strategy focused connected reducing aboriginal “primary progression.”
Arcus ended Q4 with $1.0 billion successful currency (after a $288M financing), guided 2026 GAAP gross of $45–55M, expects operating expenses to decline, and says currency should money operations into astatine slightest H2 2028.
Interested successful Arcus Biosciences, Inc.? Here are 5 stocks we similar better.

From laggards to leaders: Small caps connected the rise

Arcus Biosciences (NYSE:RCUS) utilized its fourth-quarter and full-year 2025 net telephone to item updated objective information for its pb oncology program, casdatifan, and to outline near-term plans for late-stage improvement successful wide compartment renal compartment carcinoma (ccRCC). Management besides discussed an emerging inflammation and immunology (I&I) portfolio and provided 2026 fiscal guidance.

CEO Terry Rosen and Chief Medical Officer Richard Markus emphasized Arcus’s extremity of establishing casdatifan arsenic a “best-in-class” HIF-2α inhibitor for ccRCC. The institution said updated results from the ARC-20 survey volition beryllium presented astatine ASCO GU, including efficacy and biomarker information intended to further differentiate casdatifan from belzutifan, the lone marketed HIF-2α inhibitor.

→ Diamondback Sees Resilient Demand Despite Cautious Guidance

MarketBeat Week successful Review – 7/10 - 7/14

Markus said the updated investigation reflects a January 30 information cutoff from 4 late-line monotherapy cohorts successful ARC-20. He noted this is the 4th clip Arcus has presented single-agent casdatifan information successful that mounting and said efficacy has continued to amended with longer follow-up.

Confirmed ORR (100 mg QD cohort): accrued from 35% astatine an August cutoff to 45%.
Confirmed ORR (pooled analysis): accrued from 31% to 35%.
Median PFS (100 mg QD cohort): 15.1 months aft 17.8 months median follow-up; Markus added that adjacent if each censored patients progressed astatine the adjacent scan, median PFS would inactive beryllium 14.4 months.
Median PFS (pooled analysis): remained 12.2 months, with patients continuing attraction beyond 12 months and adjacent beyond 24 months.

Management compared those outcomes to belzutifan information from LITESPARK-005, citing a 5.6-month PFS fig for belzutifan successful the aforesaid late-line setting, and argued that casdatifan monotherapy has shown longer progression-free endurance and higher effect rates.

Read Entire Article